Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 522

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4‐related systemic disease

Khosroshahi, Arezou, Bloch, Donald B., Deshpande, Vikram, Stone, John H.·2010·Arthritis & Rheumatism
DOI 10.1002/art.27435
Open this paper in CoChat — free account

Abstract

Objective: Patients with IgG4‐related systemic disease (IgG4‐RSD) frequently show an incomplete response to treatment with glucocorticoids and traditional disease‐modifying antirheumatic drugs (DMARDs). B lymphocyte depletion is a therapeutic strategy known to be effective for pemphigus vulgaris, an autoimmune condition mediated by IgG4 autoantibodies. This study was performed to assess the clinical and serologic responses to B lymphocyte depletion therapy with rituximab in patients with IgG4‐RSD. Methods: Four patients with IgG4‐RSD were treated with 2 intravenous doses (1 gram each) of rituximab. Clinical improvement was assessed by monitoring the tapering/discontinuation of prednisone and DMARDs, and by measuring the serum concentrations of B lymphocytes, immunoglobulins, and IgG subclasses before and after therapy. Results: Clinical features of IgG4‐RSD in these 4 patients included autoimmune pancreatitis, sclerosing cholangitis, lymphoplasmacytic aortitis, salivary gland involvement, orbital pseudotumor, and lacrimal gland enlargement. The 3 patients with elevated serum IgG and IgG4 levels at baseline had a mean IgG concentration of 2,003 mg/dl (normal range 600–1,500 mg/dl) and a mean IgG4 concentration of 2,160 mg/dl (normal range 8–140 mg/dl). Among these patients, the serum IgG4 concentrations declined by a mean of 65% within 2 months of rituximab administration. All 4 patients demonstrated striking clinical improvement within 1 month of the initiation of rituximab therapy, and tapering or discontinuation of their treatment with prednisone and DMARDs was achieved in all 4 patients. A decrease in IgG concentration was observed for the IgG4 subclass only. Conclusion: Treatment with rituximab led to prompt clinical and serologic improvement in these patients with refractory IgG4‐RSD, and is a viable treatment option for this condition. The decline in serum IgG4 concentrations was substantially steeper than that of the autoantibody concentrations in immune‐mediated conditions in which rituximab is effective, such as in rheumatoid arthritis. In addition, the reduction in IgG‐subclass levels appeared to be specific for IgG4. The swift improvement of IgG4‐RSD suggests that rituximab achieves its effects in IgG4‐RSD by depleting the pool of B lymphocytes that replenish short‐lived IgG4‐secreting plasma cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.27435

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 522

Metadata

Authors
Khosroshahi, A., Bloch, D. B., Deshpande, V., & Stone, J. H.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2010-05-28
Volume
62
Issue
6
Pages
1755-1762
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
DOI
10.1002/art.27435
OpenAlex
W2046297453
Cited by
522
References
21
FWCI
27.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4‐related systemic disease. https://app.cochat.ai/papers/10.1002/art.27435
The paper
Khosroshahi, A., Bloch, D. B., Deshpande, V., & Stone, J. H. (2010). Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4‐related systemic disease. Arthritis & Rheumatism. https://doi.org/10.1002/art.27435

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.